Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Opioids in Medicare Part D: Concerns about Extreme Use and Questionable Prescribing

Related Content

Media Materials


Opioid abuse and overdose deaths are at epidemic levels in the United States. This data brief is part of a larger strategy by the OIG to fight the opioid crisis and address one of its top priority outcomes-to protect beneficiaries from prescription drug abuse. It provides baseline data on the extent to which beneficiaries receive extreme amounts of opioids and appear to be "doctor shopping." It also identifies prescribers who have questionable opioid prescribing patterns.


We based this data brief on an analysis of prescription drug event records of opioids received in 2016. We determined beneficiaries' morphine equivalent dose (MED), which is a measure that equates all of the various opioids and strengths into one standard value.



Ensuring the appropriate use and prescribing of opioids is essential to protecting the health and safety of beneficiaries and the integrity of Part D. Prescribers play a key role in combatting opioid misuse. They must be given the information and tools needed to appropriately prescribe opioids when medically necessary. At the same time, we must address prescribers with questionable prescribing patterns for opioids to ensure that Medicare Part D is not paying for unnecessary drugs that are being diverted for resale or recreational use. OIG is committed to continuing investigations and evaluations to address this issue.

In addition, we are committed to forging expanded partnerships among Federal agencies, States, and private sector partners. We specifically call on Part D sponsors to work with OIG and CMS to further improve efforts to combat opioid misuse in Medicare. We also encourage Part D sponsors to effectively use CMS's Overutilization Monitoring System, which identifies beneficiaries who are potentially overutilizing opioids. We further encourage sponsors to implement drug management programs for at-risk beneficiaries, following additional guidance from CMS. By working together and expanding our efforts in Part D, we can help curb the opioid crisis in our Nation.